Barbara Farkas

1 Introduction The outbreak of the pathogenic SARS coronavirus 2 (SARS-CoV-2) and the ensuing COVID-19 pandemic claimed almost 18.2 million lives in 2020 and 2021 alone[1] and had a major impact on health care systems and economies. To date, only three antiviral agents, targeting the main viral protease or the viral RNA polymerase, are approved and effective for COVID-19 therapy.[2-4] However, resistance development and unwanted side effects can limit the clinical usefulness of these agents.